Iżrael - Ebrajk - Ministry of Health

abic marketing ltd, israel - prasugrel as hydrobromide - טבליות מצופות פילם - prasugrel as hydrobromide 5 mg - prasugrel

Iżrael - Ebrajk - Ministry of Health

trima israel pharmaceutical products maabarot ltd - prasugrel - טבליות מצופות פילם - prasugrel 10 mg - prasugrel

Iżrael - Ebrajk - Ministry of Health

trima israel pharmaceutical products maabarot ltd - lamotrigine - טבליה - lamotrigine 25 mg - lamotrigine - lamotrigine - epilepsy : monotherapy in adults and children over 12 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seiaures. primary generalised tonic clonic seizures. add- on therapy in adults and children over 2 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seizures. primary generalised tonic clonic seizures. adults ( 18 years of age and over) : lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Iżrael - Ebrajk - Ministry of Health

trima israel pharmaceutical products maabarot ltd - lamotrigine - טבליה - lamotrigine 50 mg - lamotrigine - lamotrigine - epilepsy : monotherapy in adults and children over 12 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seiaures. primary generalised tonic clonic seizures. add- on therapy in adults and children over 2 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seizures. primary generalised tonic clonic seizures. adults ( 18 years of age and over) : lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Iżrael - Ebrajk - Ministry of Health

trima israel pharmaceutical products maabarot ltd - lamotrigine - טבליה - lamotrigine 100 mg - lamotrigine - lamotrigine - epilepsy : monotherapy in adults and children over 12 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seiaures. primary generalised tonic clonic seizures. add- on therapy in adults and children over 2 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seizures. primary generalised tonic clonic seizures. adults ( 18 years of age and over) : lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Iżrael - Ebrajk - Ministry of Health

trima israel pharmaceutical products maabarot ltd - lamotrigine - טבליה - lamotrigine 200 mg - lamotrigine - lamotrigine - epilepsy : monotherapy in adults and children over 12 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seiaures. primary generalised tonic clonic seizures. add- on therapy in adults and children over 2 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seizures. primary generalised tonic clonic seizures. adults ( 18 years of age and over) : lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Iżrael - Ebrajk - Ministry of Health

teva pharmaceutical indust.ltd - levetiracetam 250 mg - tablets - levetiracetam - - levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.- levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Iżrael - Ebrajk - Ministry of Health

teva pharmaceutical indust.ltd - levetiracetam 500 mg - tablets - levetiracetam - - levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.- levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Iżrael - Ebrajk - Ministry of Health

teva pharmaceutical indust.ltd - levetiracetam 1000 mg - tablets - levetiracetam - - levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.- levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Iżrael - Ebrajk - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 2 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.